This oligonucleotide with a dual-function on targeting both TLR7 and TLR9 is able to reduce autoantibodies and improve disease symptoms in lupus-prone mice (144, 145) as well as to reverse TLR7/TLR9-mediated glucocorticoid resistance of SLE in mice, suggesting a potential therapeutic opportunity as corticosteroid drug (154). Here, TLR7 is linked to systemic lupus erythematosus.